The largest light-and-sound trial ever run has finished. Nobody has seen the results.
Cognito Therapeutics' HOPE trial puts 673 people with Alzheimer's through 12 months of daily 40 Hz light and sound against a sham. It completed in August 2026 and no results are posted. Here is what it tests and which five numbers to read first.
The HOPE trial from Cognito Therapeutics is a trial of light and sound in 673 people who have Alzheimer’s disease. It reached final completion on 17 August 2026, and as of 10 November 2026 the registry still shows no results. The participants are 50 years old or older, and each one runs 60 minutes of 40 Hz light and sound at home every day for around 12 months. They are randomly assigned to an active Spectris AD device or to a sham version of the same device, and the participants, care partners, investigators and outcome assessors are all masked. The entry on ClinicalTrials.gov has the words COMPLETED and hasResults: false. That entry shows the trial is finished, but it shows no findings. This post explains what the trial measures, why results appear after a study ends and what data to check first when the report is public.
What the HOPE trial actually tests
The trial includes 673 participants aged 50 and over - far larger than any other controlled trial of sensory stimulation. Each one uses a Spectris AD device, active or sham, at home for an hour each day between 13 December 2022 and 17 August 2026.
The primary endpoint is how much the score changes from baseline to 12 months on the iADMARS. The iADMARS combines the Mini-Mental State Examination and the Alzheimer’s Disease Cooperative Study Activities of Daily Living inventory. The study measures cognition and function together. The MMSE, ADCS-ADL and ADCS-iADL are secondary endpoints. Masking is quadruple. The registry says the phase isn’t applicable because this is a pivotal device study rather than a drug trial, so “Phase 3” isn’t the right label for it.
Why “completed” is not “positive”
The completion date is the day of the final visit of the last person in the study - it has no data about the outcome. Researchers lock the database, unblind the groups, analyse the data and send documents to regulators after this date. Companies that test devices often need multiple months before they put results on a registry. They frequently share the information at a conference or in a paper first. A period of 3 months without news is common. It doesn’t indicate success or failure. Read “completed, no results” as a date and nothing more.
The five numbers that will decide it
| Data point | Why this data point matters |
|---|---|
| Effect size on iADMARS, with the 95% confidence interval | A point estimate with an interval crossing zero is not a result, however small the p-value looks in a press release |
| Adherence | Using a device for an hour every day for a full year is hard. If only the people who used it as directed show changes, the study means something different |
| Dropouts in each group | If the active group and the sham group have different dropout numbers, the groups are no longer balanced by random assignment |
| Adverse events | People use the device every day for a year, so the report has to show its safety, not only its efficacy |
| Blinding status | The sham device also flickers. If participants could tell which group they were in more often than chance allows, expectations shaped the data |
The main point will be the effect size. The other four tell you what that number is worth.
A negative result worth more than most press releases
A July 2026 preprint describes an experiment where stimulation alters brain signals without altering behaviour. In 24 healthy people, 40 Hz flicker through wearable shutter glasses plus 40 Hz amplitude-modulated sound raises 40 Hz EEG power and phase coherence. The study doesn’t reproduce an earlier finding about audiovisual phase offsets and associative memory accuracy. The stimulation hits its target and the memory measure doesn’t move. It is small, single-session, in healthy volunteers, and not yet peer reviewed - which is exactly why it is a reason to be careful, not a final answer.
Entrainment is not outcome
Other papers show the same pattern. A comparative narrative review of 40 Hz stimulation across modalities, published in July 2026, says that single sessions reliably cause physiological entrainment but don’t reliably improve cognition. Protocols that last multiple weeks show preliminary changes in brain signals or biomarkers in selected populations. An October 2026 primate preprint reports that gamma-range stimulation of the hippocampus and entorhinal area doesn’t improve associative memory and often makes it temporarily worse - that study uses invasive electrodes in two animals. It doesn’t directly apply to non-invasive light and sound - it only shows that more gamma activity isn’t always helpful.
We keep a running index of this evidence, including the studies that don’t help our case, in every study we cite about light and sound. Our earlier look at what the 40 Hz Alzheimer’s data shows covers the pre-HOPE picture.
What a positive result would, and would not, mean for a phone app
If the HOPE trial has positive results, that’s evidence about a prescription device. People with diagnosed Alzheimer’s disease use it for an hour a day under medical supervision, and are measured on a dementia scale. None of those facts apply to software on a phone and we don’t say they do. 6th Mind is free, isn’t a medical device and isn’t a treatment for any disease - its six 40 Hz gamma sessions run 11 minutes, with a 6-minute version, and are meant for the half hour before focused work.
What our own approach rests on is separate and much smaller - our practice office in Sofia, where two minutes of EEG are recorded with a Muse band before and after every audio-visual entrainment session. We have run more than 1000 sessions with 170 people, and about 80% of programmes that reached 10 or more sessions (n≈70) improved on our EEG baseline index. Those are completers, and not every programme runs that long. Clinically based, not clinically proven. HOPE is a far better test than anything we have, which is why its result matters to us whichever way it goes.
What we will write when the numbers appear
We are committing to the scorecard above in advance: effect size with its interval, adherence, dropout by arm, adverse events, and whether blinding held. If the trial has negative results, we’ll write them up in the same language we would use for positive ones.
Sources
- “A Pivotal Study of Sensory Stimulation in Alzheimer’s Disease (HOPE Study), NCT05637801” - ClinicalTrials.gov, registry record checked 10 November 2026
- “Audiovisual stimulation using wearable shutter glasses robustly evokes 40 Hz neuronal activity but does not modulate associative memory” - bioRxiv preprint, 2026
- “Effects of 40 Hz Brain Stimulation Across Modalities: A Comparative Narrative Review” - Brain Sciences, 2026
- “Gamma and theta-burst stimulation of the hippocampus and entorhinal area transiently disrupts memory” - bioRxiv preprint, 2026
